Skip to main content
AIRS logo

AIRS · Airsculpt Technologies, Inc.

Track AIRS — free
$0.72 -0.12 (-14.04%)
Market Cap
$61.88M
Shares
73.93M
Volume · Nov 16 715.84K Avg daily vol (3M) 1.14M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.84 Open$0.78 Day$0.68–0.84 52W close$0.53–5.72 Avg vol 30d1.4M Short int3.2M · 4.4% of shares · 4.0d Short vol47% Last earningsNov 6, 2026 DataOct 2021–Nov 2026 Filing10-Q · Nov 6

Up next

Feb 5, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 6
Earnings call
Revenue falls 8.7%; full-year guidance cut

AirSculpt reported third-quarter revenue of $31.9 million, down 8.7%, and cut full-year 2026 revenue guidance to $144 million to $146 million and adjusted EBITDA guidance to $9 million to $10 million after weaker marketing productivity and center execution.

4 source passages
Welcome to the AirSculpt Technologies 3rd Quarter 2026 Earnings Call. Our third quarter results were disappointing. While we expected a revenue decline, our performance fell short of our goals, reflecting lower productivity from our marketing investments and underperformance in a handful of clinics. Revenue was $31.9 million, a decrease of 8.7% versus the prior year quarter. We now expect revenue of $144 million to $146 million, compared to Our previous outlook of $151 million to $157 million. And adjusted EBITDA of $9 million to $10 million, compared to our previous outlook of $12 million to $14 million. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue Declines on Lower Same-Center Volume

AirSculpt Technologies, Inc. reported that revenue decreased $4.1 million, or 3.5%, for the nine months ended September 30, 2026 compared to the same period in 2025, driven primarily by a 2.1% decrease in same center volume.

Revenue $31.94M ▼ 8.7% Net loss $7.17M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
references to the “Company,” “AirSculpt,” “we,” “us” and “our” refer to AirSculpt Technologies, Inc. and its consolidated subsidiaries and its related Professional Associations. Our revenue decreased $4.1 million, or 3.5%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025. This decline was driven primarily by 2.1% decrease in same center volume and a .2% decrease in average selling price on a same-center basis. Open the document at this passage
Nov 6
Current report 8-K Events of Nov 5
$39.0 million term loan refinances existing credit facility

AirSculpt Technologies entered a $39.0 million senior secured term loan and up to $5.0 million revolving facility on November 5, 2026, repaying its existing credit agreement in full; the facilities mature November 5, 2031.

Entered into a material agreement, Ended a material agreement, Financial results, New debt or off-balance-sheet obligation Read from the first part of this long document
4 source passages
On November 5, 2026 (the “Closing Date”), AirSculpt Technologies, Inc. (the “Company”), EBS Intermediate Parent LLC, a wholly-owned subsidiary of the Company (“EBS Parent”), and EBS Enterprises LLC, a wholly-owned subsidiary of EBS Parent (the “Borrower”), entered into a Financing Agreement (the “Financing Agreement”) with the lenders from time to time party thereto (the “Lenders”) and Blue Torch Finance LLC, as administrative agent and collateral agent (the “Agent”). The Financing Agreement provides for (i) a $39.0 million senior secured term loan (the “Term Loan”), funded in full on the Closing Date, and (ii) a senior secured revolving credit facility of up to $5.0 million (the “Revolving Facility” and, with the Term Loan, the “Credit Facilities”), none of which was drawn at closing. The Credit Facilities mature on November 5, 2031. On the Closing Date, the Borrower used the proceeds of the Term Loan to repay in full all outstanding obligations under the Existing Credit Agreement, following which no obligations remained outstanding and the Existing Credit Agreement, the related loan documents and the related liens and guarantees were terminated and released. Open the document at this passage
Nov 6
Current report 8-K
Revenue declines, guidance cut and debt maturity extended

AirSculpt Technologies reported third-quarter revenue of $31.9 million, down 8.7%, and cut 2026 revenue guidance to approximately $144 million to $146 million and Adjusted EBITDA guidance to approximately $9 million to $10 million. It also refinanced its term loan, extending maturity to 2031.

Financial results
5 source passages
On November 6, 2026 , AirSculpt Technologies, Inc. (the “Company”) issued a press release announcing results for the three and nine months ended September 30, 2026. Revenue was $31.9 million, a decline of 8.7% from $35.0 million in the fiscal year 2025; Revenue in the range of approximately $144 million to $146 million, compared to the previous range of $151 million to $157 million; and Adjusted EBITDA in the range of approximately $9 million to $10 million, compared to the previous range of $12 million to $14 million. maturing on November 5, 2031 and consisting of a senior secured (i) term loan facility with an aggregate principal amount of $39.0 million, which was funded in full at closing Open the document at this passage
Aug 12
Current report 8-K Events of Aug 5
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$147.68M
Trailing 12 months
Net income (TTM)
−$9.40M
Trailing 12 months
Revenue growth YoY
-8.7%
Year over year
Operating margin
-4.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$21.48M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.2%
Year over year · more shares
Price change (1Y)
-85.4%
Trailing year
Short interest
4.4%
Latest settlement · 4.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26

TL;DR. AirSculpt reported Q2 revenue down 3% to $42.9M with adjusted EBITDA of $4.9M (vs. $5.8M), cut its full-year adjusted EBITDA outlook to $12–$14M, and reaffirmed revenue at the low end of $151–$157M; same-center cases grew 1% and the company expanded its AlloClae partnership and new procedures, while customer acquisition cost rose to ~$3,500 from $2,900.

Bullish
  • + Same-center case volume grew 1.0% in Q2 and 1.1% YTD versus prior year.
  • + Entered an exclusive AlloClae partnership and is piloting the new procedure later this quarter.
  • + Skin tightening and skin removal procedures carry similar ~60% gross margin profile to core fat removal business and lift average ticket.
Bearish
  • − Q2 revenue declined 3% to $42.9M and YTD revenue fell 1.3% to $82.3M.
  • − Adjusted EBITDA fell to $4.9M in Q2 from $5.8M and YTD to $8.2M from $9.6M, with margins compressing to 11.5%/10.0% from 13.3%/11.5%.
  • − Full-year 2026 adjusted EBITDA outlook reduced to approximately $12–$14M.
  • − Full-year 2026 revenue reaffirmed only at the lower end of the $151–$157M guidance range.
  • − Q2 customer acquisition cost rose to ~$3,500 from ~$2,900 a year ago, lifting marketing to ~20% of revenue from ~18%.
  • − Q2 net loss widened to $1.1M from $0.6M and YTD net loss to $3.5M from $3.4M.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −72%
below
Price vs 50-day avg −51%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 6%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −34%
trailing
6-month return −85%
trailing
YTD return −58%
this year
Relative strength −85%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
78 of 103 funds reported for Sep 30 · net -1.4M sh shares · +11 new
Insider flow Accumulating
Net +$24.0K over 90 days · 0% sells
Short interest Rising
4.38% of shares out · ▲ +9.6% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
103 holders — near 3-yr high, broad support
Squeeze score 69
elevated · 0–100
Fundamentals
Weak
Revenue growth −16%
Y/Y
EPS growth −36%
Y/Y
Free cash flow $692.0K
Balance sheet $47.6M
net debt
Quant / Vol
risk profile
Very High
Volatility 142%
annualized · 1-yr
Max drawdown −91%
past year
ATR 23.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 7
Latest guidance · from the 8-K filed Nov 6, 2026
Revenue · full-year 2026 Lowered $144M – $146M
Aug 10, 2026 $151M – $157M changed to Nov 6, 2026 $144M – $146M
prior FY $151.82M midpoint −4.5% Y/Y
Adjusted EBITDA · full-year 2026 Non-GAAP Lowered $9M – $10M
Aug 10, 2026 $12M – $14M changed to Nov 6, 2026 $9M – $10M
Prior guidance period ended · from the 8-K filed Apr 2, 2026
Revenue · first quarter 2026 $38.5M – $39.5M
Guided vs delivered · last 7 settled
Revenue Q1 2026
guided $38.5M – $39.5M
$39.39M In line
Revenue 2025
guided $153M
$151.82M Miss −0.8%
Revenues full year 2024
guided $180M – $190M
$180.35M In line
2023 revenue full year 2023
guided $196M
$195.92M Miss −0.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−72% Bearish
Price vs 50-day avg
−51% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
6% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
78 of 103 funds reported for Sep 30 · net -1.4M sh shares · +11 new
Insider flow Accumulating
Net +$24.0K over 90 days · 0% sells
Short interest Rising
4.38% of shares out · ▲ +9.6% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
103 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 6% Range high $6
vs 200-day avg -72% vs 50-day avg -51%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted net loss per share of common stock - Basic non-GAAP -$0.09 Nine Months Ended September 30, 2026 —
Adjusted net loss per share of common stock - Diluted non-GAAP -$0.09 Nine Months Ended September 30, 2026 —
Adjusted Net Income per share - Basic non-GAAP $0.01 Three Months Ended June 30, 2026 filing —
Adjusted Net Income per share - Diluted non-GAAP $0.01 Three Months Ended June 30, 2026 filing —
Customer acquisition costs $3,467 the three months ended June 30, 2026 filing —
Same center case volume growth 1% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AIRS
Airsculpt Technologies, Inc.
this stock
$61.88M -57.7% -15.8% — 4.4%
HCA
HCA Healthcare, Inc.
$104.25B +6.9% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.34B +3.3% — — 0.0%
THC
Tenet Healthcare Corp
$22.76B +43.9% +0.9% 8.3 2.2%
EHC
Encompass Health Corp
$13.83B +32.8% +10.5% 22.0 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
104
% held
59.8%
Reported
78 of 103
Top holder
Vesey Street Capital Part…
Held Float
View
Held by Funds
Fund positions
82
View
Short & Settlement
Short Interest Rising
Shares short
3.2M
Days to cover
4.0d
Change
+283.7K sh
View
Short Volume
Short vol %
47%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
43.8K
Value
$73.2K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
57.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$24.0K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$151.8M
Net income (FY)
$-11.7M
EPS diluted
$-0.19
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 6, 2026
This year
20

AirSculpt Technologies entered a $39.0 million senior secured term loan and up to $5.0 million revolving facility on November 5, 2026, repaying its existing credit agreement in full; the facilities mature November 5, 2031.

View
Proposed Sales
Value
$16.7K
Shares
2.6K
Filed
Nov 15, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 6, 2026
View
Investor Relations
Latest news
AirSculpt Technologies Announces…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
AIRS +56.8% -34.4% -84.8% -51.6% -57.7%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +54.2% -33.2% -85.3% -51.4% -68.4%

Capital returns

Latest dividend
$0.41 / share · ex Aug 25, 2022
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1870940 CUSIP 009496100 13F (30d) 77 filings 63 filers Visit website Investor relations